Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results.
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi
Regeneron beats Q2 EPS estimate
Adj EPS USD 14.29 (est USD 10.3) - Rev USD 4,291M (Est USD 3,816M) - Dupixent Global Net Sales Rise 38% To $6B -Q2 EYLEA HD US Net Sales UP 52% To $596M
REGN Regeneron RESULTS: Q2, Q2 ADJ EPS $14.29 vs. EST $10.3, Q2 REV $4.291B vs. EST $3.816B, Q2 EPS $12.23, Regeneron Earnings Notes:, Outlook FY CAPEX $1,030-1.100B, Q2 dupixent global net sales rise 38% to $6B, Q2 eylea hd U.S. net sales up 52% to $596M